1. Scrip
  2. >>Business

GSK Spin-Off Launches KaNDy To Tackle Key Symptoms Of Menopause

 
• By Kevin Grogan

NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.

Launch
Ready for lift-off: KaNDy is a new firm dedicated to women's health • Source: Shutterstock

KaNDy Therapeutics has been launched by GlaxoSmithKline PLC spin-off NeRRe Therapeutics Ltd. to maximize a potential breakthrough medicine that could provide a more effective alternative to hormone replacement therapy (HRT) for post-menopausal vasomotor symptoms.

NeRRe was founded in 2013, stocked with GSK's portfolio of neurokinin (NK)-1 receptor antagonists, and two candidates have emerged in early-stage trials

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.